Bortezomib and cyclophosphamide in combination with dexamethasone has already demonstrated
high response rates in refractory multiple myeloma. Low dose continuous cyclophosphamide,
also called metronomic scheduling, minimize toxic side effects and eliminate the obligatory
rest periods. Combining cyclophosphamide with bortezomib might target distinct aspects of a
myeloma functionality.
The objectives of the present study are whether patients with refractory or relapsed multiple
myeloma after reinduction with bortezomib, cyclophosphamide and dexamethasone will benefit
from maintenance therapy with bortezomib and cyclophosphamide with acceptable side-effects.
Recently two studies have shown with thalidomide that maintenance therapy might improve EFS
and one study also the OS.